Psychosocial Outcomes After Initial Treatment of Erectile Dysfunction with Tadalafil Once Daily, Tadalafil on Demand or Sildenafil Citrate on Demand: Results from a Randomized, Open-label Study

Overview

Journal Int J Impot Res

Specialties Reproductive Medicine
Urology

Date 2014 May 3

PMID 24784894

Citations 6

Authors

K Hatzimouratidis

J Buvat

H Buttner

P A S Vendeira

I Moncada

M Boehmer

C Henneges

F G Boess

Affiliations

Soon will be listed here.

Abstract

Initiation of ED treatment with a particular PDE5I may influence treatment-adherence and other outcomes. In this multicenter, open-label study, men with ED, naïve to PDE5I, were randomized to tadalafil 5 mg once-a-day (OaD; N=257), 10 mg on demand (PRN; N = 252) or sildenafil-citrate (sildenafil) 50 mg PRN (N = 261) for 8 weeks (dose adjustments allowed), followed by 16 weeks of pragmatic treatment (switching between PDE5I allowed). Primary outcomes (treatment-adherence) were reported previously. Here, we report effects on: Psychological and Interpersonal Relationship Scales, Self-Esteem and Relationship (SEAR) questionnaire, ED Inventory of Treatment Satisfaction (EDITS), International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) and Global Assessment Questions (GAQ). Mixed-model for repeated measures and analysis of covariance were used to analyze changes from baseline; GAQ-responses were evaluated by logistic regression. Analyses were adjusted for treatment, country, ED-severity, baseline and baseline-by-treatment interaction. Patients randomized to tadalafil OaD or PRN reported greater improvement (least-square mean (s.e.) change) in Sexual Self-Confidence (OaD +0.90 (0.048), PRN +0.93 (0.050), vs +0.73 (0.049); P=0.006 and P=0.001) and Spontaneity (OaD +0.11 (0.035), PRN +0.13 (0.035), vs +0.02 (0.035); P = 0.044 and P = 0.010) compared with sildenafil. Improvements in GAQ and SEP responses, IIEF-EF, orgasmic function, sexual desire, overall satisfaction domains, SEAR and EDITS scores did not differ significantly between treatment groups.

Citing Articles

Bedtime sildenafil oral suspension improves sexual spontaneity and time-concerns compared to on-demand treatment in men with erectile dysfunction: results from a real-life, cross-sectional study.

Boeri L, Palumbo F, Cai T, Miacola C, Ceruti C, Bitelli M Int J Impot Res. 2025; .

PMID: 39994340 DOI: 10.1038/s41443-025-01035-4.

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts.

Miller K, May U, Beecken W, Hatzichristodoulou G, Bohm M, Fink S Front Pharmacol. 2023; 14:1254706.

PMID: 37876727 PMC: 10590875. DOI: 10.3389/fphar.2023.1254706.

Canadian Urological Association guideline: Erectile dysfunction.

Domes T, Tadayon Najafabadi B, Roberts M, Campbell J, Flannigan R, Bach P Can Urol Assoc J. 2021; 15(10):310-322.

PMID: 34665713 PMC: 8525522. DOI: 10.5489/cuaj.7572.

Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.

Madeira C, Tonin F, Fachi M, Borba H, Ferreira V, Leonart L World J Urol. 2020; 39(3):953-962.

PMID: 32388784 DOI: 10.1007/s00345-020-03233-9.

Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction.

Zhou Z, Chen H, Wu J, Wang J, Zhang X, Ma J Sex Med. 2019; 7(3):282-291.

PMID: 31307951 PMC: 6728809. DOI: 10.1016/j.esxm.2019.06.006.

References

Althof S . When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res. 2002; 14 Suppl 1:S99-S104. DOI: 10.1038/sj.ijir.3900799. View

Rajfer J, Aliotta P, Steidle C, Fitch 3rd W, Zhao Y, Yu A . Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2006; 19(1):95-103. DOI: 10.1038/sj.ijir.3901496. View

Walker D, Ackland M, JAMES G, Muirhead G, Rance D, Wastall P . Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999; 29(3):297-310. DOI: 10.1080/004982599238687. View

Gingell C, Sultana S, Wulff M, Gepi-Attee S . Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med. 2006; 1(2):179-84. DOI: 10.1111/j.1743-6109.2004.04026.x. View

Tsertsvadze A, Fink H, Yazdi F, MacDonald R, Bella A, Ansari M . Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009; 151(9):650-61. DOI: 10.7326/0003-4819-151-9-200911030-00150. View

Althof S, Corty E, Levine S, Levine F, Burnett A, McVary K . EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999; 53(4):793-9. DOI: 10.1016/s0090-4295(98)00582-2. View

Brock G, McMahon C, Chen K, Costigan T, Shen W, Watkins V . Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002; 168(4 Pt 1):1332-6. DOI: 10.1016/S0022-5347(05)64442-4. View

Montorsi F, Aversa A, Moncada I, Perimenis P, Porst H, Barker C . A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. J Sex Med. 2011; 8(9):2617-24. DOI: 10.1111/j.1743-6109.2011.02353.x. View

Forgue S, Patterson B, Bedding A, Payne C, Phillips D, Wrishko R . Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006; 61(3):280-8. PMC: 1885023. DOI: 10.1111/j.1365-2125.2005.02553.x. View

10.

Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6):822-30. DOI: 10.1016/s0090-4295(97)00238-0. View

11.

Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves L . Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008; 5(9):2160-9. DOI: 10.1111/j.1743-6109.2008.00935.x. View

12.

Buvat J, Buttner H, Hatzimouratidis K, Vendeira P, Moncada I, Boehmer M . Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med. 2013; 10(6):1592-602. DOI: 10.1111/jsm.12130. View

13.

Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R . Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003; 62(1):121-5; discussion 125-6. DOI: 10.1016/s0090-4295(03)00359-5. View

14.

Hatzichristou D, Haro J, Martin-Morales A, von Keitz A, Riley A, Bertsch J . Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract. 2007; 61(11):1850-62. DOI: 10.1111/j.1742-1241.2007.01560.x. View

15.

Hellstrom W, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T . Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002; 23(6):763-71. View

16.

Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F . Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010; 57(5):804-14. DOI: 10.1016/j.eururo.2010.02.020. View

17.

Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J . Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009; 6(7):2039-48. DOI: 10.1111/j.1743-6109.2009.01301.x. View

18.

El Khiat Y, Ghazi S, Allam A, Khawaja M, Belger M, Tamer M . Psychosocial impact and effectiveness of tadalafil among treatment-naïve and previously-treated men with erectile dysfunction in Saudi Arabia and other Gulf-region countries. Curr Med Res Opin. 2008; 24(7):1965-73. DOI: 10.1185/03007990802190641. View

19.

Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998; 338(20):1397-404. DOI: 10.1056/NEJM199805143382001. View

20.

Cappelleri J, Althof S, Siegel R, Shpilsky A, Bell S, Duttagupta S . Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction. Int J Impot Res. 2004; 16(1):30-8. DOI: 10.1038/sj.ijir.3901095. View